Ferring Pharmaceuticals and the Chinese Academy of Sciences (CAS) have forged a long-term collaboration to advance basic and translational research in reproductive medicine.
As part of the agreement, a new jointly funded laboratory will be created within the CAS research facility in Beijing, China.
It will accomplish this through the development of novel product candidates and therapeutics strategies.
Known as the ‘Ferring Institute of Reproductive Medicine’, the facility will bring together researchers from both Ferring and CAS to find solutions to address global challenges in fertility and high rates of obstetric complications.
“Across the world, too many couples still face considerable challenges when trying to become families,” said Per Falk, Executive Vice President and Chief Scientific Officer, Ferring Pharmaceuticals.
“This collaboration forms the next phase in our ongoing efforts to advance knowledge and care in reproductive medicine and women’s health.
“Working together we hope to gain a deeper understanding of fertility and implantation and discover new solutions that could transform the way in which reproductive medicine is managed in the future.”
For CAS, the collaboration will provide additional expertise and funding to support their world-class stem cell research and regenerative medicine programme, a core element of their Innovation 2030: Building Tomorrow initiative.
For Ferring, the collaboration will help to identify new therapeutic concepts and targets that will enable the discovery of novel drug candidates that may be further developed to address unmet needs in reproductive medicine and women’s health.